Astria Therapeutics Inc (ATXS) USD0.001
Sell:$3.50Buy:$7.70
$0.04
(0.77%)
- This stock can be held in a
Stocks and Shares ISA$0.04
(0.77%)$0.04
(0.77%)Company Information
About this company
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
Key people
Key facts
- EPICATXS
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS04635X1028
- Market cap$293.46m
- Employees78
- Shares in issue56.43m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.